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Vault changes after cyclopentolate 
instillation in eyes with posterior 
chamber phakic intraocular lens
Beatriz Gargallo-Martinez  1,2 ✉, Jose Javier Garcia-Medina  3,4 ✉, Elena Rubio-Velazquez1,3, 
paulo fernandes5, César Villa-collar1,6, José M. Gonzalez-Meijome5 & Ramón Gutierrez-
ortega1,4
posterior chamber phakic intraocular lens (pioL) implantation is a common option for correcting 
moderate-to-high ocular refractive defects. Because this pIOL is implanted on ciliary sulcus, the 
distance between the back surface of the pIOL and the anterior surface of the crystalline lens, that 
it is known as vault, should be measured in different conditions to ensure the technique’s safety. 
Cyclopentolate is a drug that dilates the pupil and relaxes accommodation (cycloplegia). It is often used 
for different ocular examinations and for other medical purposes. However, there is no evidence of the 
effect of this drug on vault. This study quantified central vault changes associated with cyclopentolate 
instillation. We measured the vault under normal conditions (pre-cycloplegic instillation) and after 
instilling cyclopentolate on 39 eyes of 39 patients with implanted pIOL. Our results suggest that 
cyclopentolate instillation may induce changes to vault in eyes with implanted pIOL. These changes 
seem safe and are mainly associated with vault under normal conditions, but also with anterior chamber 
depth, pupillary diameter and pIOL size.
Visian Implantable Collamer Lens (ICL, STAAR Surgical) is a foldable posterior chamber phakic intraocular lens 
(pIOL) designed to correct moderate-to-high myopia1. The latest models have a central hole that allows better 
aqueous humour exchange between the anterior and posterior chambers without the need for iridotomy2. These 
models present safe and efficacious results as previous models with no hole3,4.
The central vault is defined as the distance between the back surface of the ICL and the anterior surface of the 
crystalline lens. An appropriate vault has been suggested to be between 250 and 750 µm5. An insufficient vault 
may induce anterior subcapsular cataract due to the contact between the ICL and the anterior lens capsule1,6,7. 
Excessive vaulting can cause angle closure, pupillary blockage or pigmentary dispersion syndrome, which can 
increase intraocular pressure and, thus, the risk of glaucoma8–11. Therefore, it is important to measure this dis-
tance to ensure the technique’s safety.
Changes in anterior segment structures appear during accommodation, such as reduced anterior chamber 
depth (ACD), inducing proximity between the anterior surface of the crystalline lens and the cornea with appear-
ance of synkinetic myosis12. The ICL is implanted in the ciliary sulcus. Given its location, dynamic interactions 
take place between the pIOL and the surrounding structures. Some authors have studied these effects on the vault 
by accommodative stimulus13–17, instillation of pilocarpine for pharmacologically-induced accommodation13,18, 
light-induced pupil constriction15,17,19 and mydriasis.20 However, no studies have quantified the cycloplegic effect 
on the central vault.
Cyclopentolate is a drug that dilates the pupil and relaxes accommodation. Preoperative and postoperative 
evaluations of post-cyclopentolate instillation (by cycloplegic eyedrops) are necessary with patients who have 
undergone refractive surgery because they allow refraction without accommodation and fundus examination. 
Cyclopentolate instillation might also be needed after pIOL implantation when other concurrent ocular diseases 
appear (uveitis, keratitis, retinal detachment and so).
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With patients who have undergone pIOL implantation, the cyclopentolate also allows the central and periph-
erical vault to be measured, but these measurements could be altered secondary to changes in the curvature of 
crystalline lens surface. We hypothesized that cyclopentolate could have an opposite effect to pilocarpine, but this 
was not always the case in our clinical practice.
The aim of the current research was to evaluate the effect of cyclopentolate on central vault measurements by 
studying the dynamic interactions between the ICL and the surrounding structures. We also considered some 
factors that could influence potential vault changes.
Results
Sample characteristics. Thirty-nine eyes of 39 patients who underwent Visian ICL were included. Patients’ 
demographic and clinical data are summarised in Table 1.
At 6 months post-surgery, the postoperative safety and the efficacy index was 1.12 ± 0.23 and 1.09 ± 0.23, 
respectively. The spherical equivalent mean improved to −0.03 ± 0.35D in the postoperative examination 
(P < 0.001). No contact between the posterior pIOL surface and the anterior crystalline lens or angle closure 
was detected in any eye in this study. Biomicroscopy showed no sign of pigmentary dispersion in any eye. 
Postoperative intraocular pressure (IOP) was 12.46 ± 2.38 mmHg (ranging from 8 to 18 mmHg) at 6 months 
post-surgery. There were no significant differences between the mean preoperative and postoperative intraocular 
pressures (p = 0.218).
Vault measurements pre- and post-cyclopentolate instillation. The mean vault under normal 
conditions (Nvault, mean: 534.6 ± 339.6 µm, ranging from 50 to 1407 µm) was significantly (p < 0.001) higher 
than the mean vault under cycloplegic conditions (Cvault, mean: 451.6 ± 259.6 µm, ranging from 63 to 1096 µm) 
(Fig. 1). However, the opposite change was observed in some patients (Fig. 2). Cvault dropped more than 20 µm 
the Nvault in 23 eyes (59%), increased more than 20 µm in eight eyes (20.5%) and was similar (change between 
−20 µm and +20 µm) in eight eyes (20.5%).
Relationship between vault change (∆vault = Cvault-Nvault) and Nvault. ∆vault correlated sig-
nificantly with Nvault (Pearson’s coefficient correlated r = −0.720, p < 0.001). (Fig. 3). In the eyes with Nvault 
<511 µm, ∆vault was significantly lower (P < 0.001) than in the eyes with Nvault ≥511 µm (+16.9 ± 76.7 µm vs. 
−168.8 ± 115.1 µm, respectively).
Nvault also correlated significantly with CVault (r = 0.932, p < 0.001) and ACD (r = 0.399, p = 0.010).
Relationship between vault change (∆vault = Cvault-Nvault) and ACD. ∆vault correlated 
significantly with ACD (Pearson’s correlation coefficient, r = −0.408, p = 0.010) (Fig. 4). In the eyes 
with ACD < 3.13 mm, ∆vault was significantly (p = 0.014) lower than in the eyes with ACD ≥ 3.13 mm 
(−34.7 ± 115.0 µm vs. −139.9 ± 138.9 µm).
Relationship between vault change (∆vault = Cvault-Nvault) and Pupillary diameter. ∆vault 
also significantly correlated with the pupillary diameter (Pearson correlation coefficient, r = 0.351, p = 0.039) 
Eyes/Patients (n) 39/39
Women (n; %) 29; 74.36%
Right eye (n; %) 22; 56.41%
ICL type
   Myopic (n; %) 30; 76.92%
   Myopic toric (n; %) 9; 23.08%
Mean SD Range [minimum, maximum]
Age (years) 35.67 8.90 [22, 52]
Sphere (D) −7.83 3.44 [−17.25, −2.00]
Cylinder (D) −1.07 0.92 [−3.25, 0.00]
Mesopic pupillary diameter (mm) 5.88 1.17 [3, 8]
Intraocular pressure (mmHg) 11.95 2.43 [8, 17]
Pachymetry (µm) 531.90 39.94 [415,617]
ACD (mm) 3.16 0.21 [2.80, 3.64]
W-W (mm) 11.94 0.38 [11.06, 12.60]
ICL power (D) −9.58 3.40 [−18.00, −3.00]
ICL size (mm)
   12.6 (n; %) 8; 20.51%
   13.2 (n; %) 27; 69.23%
   13.7 (n; %) 4; 10.26%
Table 1. Patients’ demographic and clinical data. SD = standard deviation; D = diopters; ACD = anterior 
chamber depth; W-W = horizontal diameter white-to-white; ICL = Implantable Collamer Lens; SE = spherical 
equivalent.
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(Fig. 5). ∆vault in the eyes with a pupil <6.00 mm was significantly (p = 0.007) more negative than in eyes with a 
pupil ≥6.00 mm (−128.2 ± 133.6 µm vs. −10.7 ± 107.3 µm, respectively).
Relationship between vault change (∆vault = Cvault-Nvault) and ICL characteristics. ∆vault 
did not significantly correlate with WW-size i.e. the difference between horizontal white-to-white diameter and 
Figure 1. OCT image of the vault measurement. (a) normal conditions (top), and (b) cycloplegic conditions 
(bottom). The measurements of the right eye of a 27-year-old patient with a 5-mm pupil, 3.4-mm ACD, 11.80-
mm W-W, 13.20-mm ICL and -10.50-diopter ICL power shows a decreased vault that resulted from cycloplegic 
drug instillation.
Figure 2. OCT image of vault measurement (a) under normal conditions (top), and (b) cycloplegic conditions 
(bottom). The measurements of the left eye of a 29-year-old patient with a 7.5-mm pupil, 2.98-mm ACD, 
11.70-mm W-W, 12.60-mm ICL and -12.50-diopter ICL power shows an increase in vault that resulted from 
cycloplegic drug instillation.
Figure 3. Scatterplot representing the linear correlation between the normal vault (Nvault) and ∆vault 
resulting from cycloplegic drug instillation. ∆vault = Cvault-Nvault. Nvault = vault under normal conditions. 
Cvault = vault after cyclopentolate instillation.
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ICL size (Pearson’s correlation coefficient, r = −0.292, p = 0.071) (Fig. 6). However, in the eyes with WW-size 
<1.1 mm, ∆vault was significantly (p = 0.026 by the t-test) lower than in the eyes with WW-size ≥1.1 mm 
(−36.7 ± 117.8 vs. −131.8 ± 138.8 µm, respectively).
Figure 4. Scatterplot representing the linear correlation between the ACD and ∆vault resulting from 
cycloplegic drug instillation. ∆vault = Cvault-Nvault. Nvault = vault under normal conditions. Cvault = vault 
after cyclopentolate instillation.
Figure 5. Scatterplot representing the linear correlation between the ∆vault and pupillary diameter resulting 
from cycloplegic drug instillation. ∆vault = Cvault-Nvault. Nvault = vault under normal conditions. 
Cvault = vault after cyclopentolate instillation.
Figure 6. Scatterplot representing the linear correlation between ∆vault and the difference in WW-ICL size 
resulting from cycloplegic drug instillation. ∆vault = Cvault-Nvault. Nvault = vault under normal conditions. 
Cvault = vault after cyclopentolate instillation. WW = White-to-white.
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Different ICL sized groups showed a distinct ∆vault (p = 0.009) (Fig. 7). The smallest ICL size (12.60 mm) 
had a mean ∆vault of +18.8 ± 85.7 µm, which was significantly lower and more positive than the largest ICL size 
(13.70 mm) with a mean ∆vault of −219.3 ± 97.5 µm (p = 0.012). The ICL size 13.2 group presented no significant 
differences in ∆vault to other ICL size groups (p = 0.090 and p = 0.171, respectively).
Nvault also differed in each ICL size (p = 0.035). The smallest ICL size presented the lowest Nvault 
(296.3 ± 262.2 µm), followed by 13.2 size (567.6 ± 333.2 µm), while the largest ICL size showed the highest Nvault 
(789.0 ± 300.3 µm).
pIOL power did not significantly correlate with ∆vault (p > 0.05).
Relationship between vault change (∆vault = Cvault-Nvault) and all parameter measured. Age 
and pachymetry did not significantly correlate with ∆vault (p > 0.05). The multiple stepwise linear regression results 
showed that the most relevant variable to ∆vault was Nvault (p < 0.001, partial regression coefficient B = −0.271; 
standardised coefficient Beta = −0.677), followed by pupillary diameter (p = 0.032, partial regression coefficient 
B = 29.05, standardised coefficient Beta = 0.251). The remaining parameters showed no statistical significance into 
multivariate analysis so they were removed. The final model obtained was good and predicted more than 50% of 
vault change (R = 0.756, R2 = 0.571, adjusted R2 = 0.547, p < 0.001). Accordingly, vault decreased after cycloplegic 
instillation as Nvault increased and pupil diameter belittled.
Discussion
Vault measurement after ICL implantation is determined to ensure surgical safety. As several parameters affected 
the vault after surgery21–24 and this can change with time25–28, accurate objective measurements are required under 
different conditions in the short and long terms to understand the dynamic interactions between the ICL and the 
surrounding structures.
The current results suggest that cycloplegic eyedrops have different effects on vault measurements, and several 
parameters may influence such changes. Figures 1 and 2 illustrate two cases with different results.
Previous studies have reported a relation among ocular size, vault degree and ICL size. While eyes with a deep 
anterior chamber and/or a high W-W have higher vaults with a bigger lens size (this case tends to oversize the 
ICL), eyes with a shallow anterior chamber and/or low W-W have lower vaults with a smaller lens size (undersizes 
the ICL)29,30. Similarly, the current results suggest that ∆vault depends on some ocular parameters. The eyes with 
a high Nvault, a deep anterior chamber or a bigger lens size showed a similar and a more marked reduction in 
vault with the cyclopentolate effect (cycloplegic eyedrops reduced Nvault). In contrast, the eyes with low Nvault, 
a narrow anterior chamber or a smaller lens size presented a less marked reduction or a higher vault value after 
instilling the cycloplegic drug.
The multiple regression analysis showed that the most important parameter for vault change after instilling 
cycloplegic eyedrops was vault under normal conditions (Nvault). Therefore, the cycloplegic effect on vault could 
be explained by changes in ciliary muscle and horizontal lens compression. Lewis et al.31 showed that maximal 
ciliary muscle thickness increased with the accommodative response and decreased under cycloplegic conditions. 
As the ICL footplate is supported in the sulcus, changes in ciliary muscle tone may modify vault. Zhu et al.20 noted 
that the distance between the corneal endothelium and the ICL significantly increased after pharmacological 
mydriasis (the ICL moved backwards). They hypothesised that this phenomenon was due to enlargement of the 
sulcus-to-sulcus distance after pharmacological ciliary muscle relaxation. Therefore, if the cycloplegic eyedrops 
reduce horizontal compression, vault should reduce. This would explain why the vault with oversized ICLs was 
affected more by a cycloplegic drug than undersized ICLs. An oversized ICL produces greater lens compression 
in the ciliary sulcus which leads to a high degree of vaulting22, which is affected more by the cycloplegic drug (the 
cycloplegic vault decreased further, as in big eyes with a deep ACD). Our results agree with the case reported by 
Bechmann et al.32 These authors showed a patient with large eyes (ACD > 3.7 mm) with increased vaulting during 
Figure 7. Mean ∆vault values resulting from cyclopentolate instillation for each ICL size. ∆vault = Cvault-
Nvault. Nvault = vault under normal conditions. Cvault = vault after cyclopentolate instillation. 
ICL = implanted collamer lens.
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the accommodative stimulus and decreased vaulting when instilling a cycloplegic drug. However, an undersized 
ICL led to a situation in which the ICL footplate was not well wedged in the ciliary sulcus. This resulted in lack of 
horizontal compression22 and low vaulting, thus cycloplegic agent would affect the vault less (Δvault came close 
to 0, as in eyes with a narrow ACD).
As pupil diameter was the second most important variable for vault change according to the multiple lin-
ear regression analysis, pupil variations and their relationship with vault were also analysed in our study. Some 
authors have reported that under photopic conditions with pupillary constriction, the distance between the ICL 
and the crystalline lens significantly decreased13,15,17,19. This has been explained by the vertical compression pro-
duced by the iris13,17. If the vault is lower when the pupil is constricted (with the photomotor reflex), it is under-
standable that the cycloplegic drug could cause the opposite effect, and vault would be similar or higher with a 
dilated pupil. However, the present results indicated the pupillary diameter effect on ∆vault under mesopic condi-
tions, we showed that small pupils had the opposite effect to what was expected (the vault decreases with cyclople-
gia), and large pupils were less affected by cycloplegic drops (the cycloplegic vault is similar or higher). Numerous 
interactions occur between the ICL and the eye, and the ICL and the vault may be influenced differently by the iris 
musculature, depending on the lighting conditions. We believe that the pupillary sphincter induces centripetal 
force on the ICL, which increases horizontal compression to cause higher vaults under mesopic conditions and, 
therefore, the cycloplegic drug eliminates this pressure and reduces the vault. This effect would be independent of 
the vertical compression produced by photomotor reflex.
Accommodation causes changes to the anterior segment, i.e., a decreased ACD due to the proximity of the 
anterior surface of the crystalline lens to the cornea by the forward bulging of the anterior lens surface and 
a smaller pupillary diameter12,33,34. If the anterior surface of the crystalline lens approaches the cornea during 
accommodation, we expect the central vault to decrease13–15,17,20 and, therefore, the distance between the ICL 
and the crystalline lens should increase when instilling a cycloplegic drug, and accommodation is no longer 
active. This would explain our results in those eyes in which a small ICL (with no horizontal compression) and/
or a low degree of vaulting had a similar or slightly higher vault when instilling a cycloplegic drug. Maldonado 
et al.35 reported a case with similar findings to our study. A patient implanted with a phakic IOL (ICL V3 model; 
11.5 mm) had a normal vault postoperatively in which the ICL came completely into contact with the anterior 
pole of the crystalline lens when 2% pilocarpine (pharmacologic accommodation) was instilled; 24 hours after 
instilling 1% cyclopentolate, the ICL vault increased to 132 μm. Zhu et al.20 showed a slight vault increase of 46 µm 
after pharmacologic mydriasis with Mydrin-P, which contains 0.5% (w/v) tropicamide and 0.5% (w/v) neophryn. 
These authors found this increase 6 months after Visian V4c implantation with 462.5 ± 162.7 µm of vault prior 
to dilation, which is comparable to our results (our patients with Nvault < 511 µm presented a slightly increased 
vault after cycloplegic eyedrops). Despite an increase in vault being expected as a result of accommodation paral-
ysis, the opposite effect shown (some lenses reducing the vault after cycloplegic instillation) cannot be explained 
by a change in crystalline lens. Zhu et al.20 also found that the vault decreased in 11 eyes of 8 patients (6.4%).
There are some methodological differences between the research performed by Zhu et al. and ours that could 
justify the different results, at least in part. Firstly, the eyedrops used in both studies were not the same (combina-
tion of tropicamide and neophryn versus cyclopentolate), which may have cause different ocular effects. Secondly, 
they mostly considered both eyes of one same patient for the analysis instead of one eye per patient, as in the pres-
ent study. Thirdly, they considered only one measurement per vault estimation, whereas we considered the mean 
of three measurements. Fourthly, the illumination conditions for vault measurements are not described in their 
study, which have been demonstrated to affect both the ICL position and the central vault17,19. The basal vault 
measure (Nvault) in our study was performed under mesopic conditions. Fifthly, they did not study the associa-
tion between ∆vault and other possible influencing factors as we did. Finally, the authors used Pentacam, whereas 
we employed anterior segment OCT to measure vault values. As recently shown by Wang et al.36, Pentacam and 
anterior segment OCT cannot be interchanged to estimate pIOL vault.
Our results also suggest that using cyclopentolate eyedrops is safe in all cases. In the eyes with high Nvaults, 
cyclopentolate was associated with a decreased vault (Fig. 3) and did not increase the risk of pigmentary glau-
coma if we consider the following facts: (a) no signs of pigmentary dispersion were detected in any eye during the 
6-month follow-up; (b) postoperative IOP at the 6-month follow-up remained unchanged and did not go beyond 
21 mmHg in any eye. In the eyes with low Nvault, no contact between the posterior pIOL surface and the anterior 
crystalline lens was detected in any eyes before or after cyclopentolate instillation. Cyclopentolate was associated 
with increased vault in these cases (Fig. 3), which minimises the risk of cataracts developing after ICL implanta-
tion. Thus, we can speculate that these eyedrops could be used as treatment in the eyes where vault is 0 (contact 
between pIOL and the crystalline lens) while waiting for ICL exchange to be performed.
All these considerations allow us to conclude that cyclopentolate instillation is not only safe 6 months after 
ICL implantation, but also offers a protective effect against pigmentary glaucoma (because this drug seems to 
decrease ∆vault in the eyes with high Nvault) and cataract formation (because it seems to increase ∆vault in the 
eyes with low Nvault).
Additional studies are necessary to confirm the current findings in order to better understand the reaction 
of the ICL under all kinds of conditions. As accommodation and the cycloplegic drug change ICL vault, it is 
reasonable to measure this distance under the effect of pilocarpine and cyclopentolate during the postoperative 
follow-up to ensure surgical technique safety. It is also important to define the different conditions needed to take 
objective vault measurements as these conditions may affect them. As supported by our results, cyclopentolate 
may induce artifactual results on vault estimations, which should be taken into account when examining eyes 
with pIOL implantation.
This is the first study to analyse the effect of cycloplegic eyedrops on ICL vault. Although the sample is rel-
atively small (n = 39), the selection of only one eye per patient and considering the mean of three measure-
ments per vault estimation confer our results reliability. Another issue is that we did not measure axial length 
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preoperatively because it was not necessary for pIOL diameter or power calculation as described in methods 
section. However, we consider that analysing the effect of axial length on ICL behaviour could be interesting for 
further studies.
In conclusion, the present results suggest that cyclopentolate eyedrops may change the mean central vault in 
eyes with pIOL implantation. This effect is related to Nvault, ACD, pupillary size and ICL size. Our results also 
indicate that cyclopentolate instillation is safe in these eyes.
Methods
Study characteristics. This prospective study included consecutive patients who underwent Visian ICL 
implantation at Clinica Oftalmologica Novovision in Murcia, Spain. The study protocol was conducted accord-
ing to the Declaration of Helsinki and was approved by the Ethics Committee from Clinica Oftalmologica 
Novovision, Murcia, Spain. Informed consent was obtained from all the patients.
Preoperative examination. A complete ocular examination was performed preoperatively to determine 
indications for ICL implantation, including topography, pachymetry, ACD measured using the Oculus Pentacam 
(Germany), horizontal white-to-white diameter (W-W) measured by Allegro Topolyser (WaveLight), pupillome-
try under mesopic conditions (Colvard Pupillometer), manifest and cycloplegic refractions, best-corrected visual 
acuity (BCVA), central corneal endothelial cell count (ECC) (Specular Microscope CEM-530, Nidek), slit-lamp 
biomicroscopy, intraocular pressure (IOP), and dilated fundus examination. The parameters of the ICL (power 
and size) were calculated using the software v4.08 of Staar Surgical S.L. (available online at https://ocos.staarag.
ch/). The keratometry, the ACD and the pachimetry were used to estimate the power of the pIOL. The W-W and 
the ACD were used to calculate the size of the pIOL. Axial length was not necessary for the calculation of pIOL 
power or size.
Visian ICL implanted. The implanted pIOLs were Visian ICL model V4C (with a central hole) and 
emmetropia was targeted. ICL size was determined for each patient according to the manufacturer’s recommen-
dations based on W-W and ACD. All surgical actions were performed by the same surgeon (R.G.O.) without 
complications, who implanted and horizontally oriented all the lenses at the Novovision Ophthalmologic Clinic, 
Murcia, Spain.
Inclusion and exclusion criteria. The inclusion criteria in this study were age >18 years, stable myopia, 
ACD ≥ 2.8 mm, ECC > 2,000 cells/mm2 and postoperative follow-up after 6 months of surgery. Only one eye per 
patient was selected. If both eyes of the same patient were eligible, a randomly selected eye was chosen. Patients 
with a history of any disease that might affect anterior segment structure function were excluded.
Postoperative examination and vault measurements. Six months after ICL implantation, the same 
series of examinations was repeated. Assessments of surgery outcomes were performed by the safety index 
(postoperative-BCVA/preoperative-BCVA) and the efficacy index (uncorrected-visual-acuity-postoperative/
BCVA-preoperative). Two different central vault measurements were also estimated by anterior segment opti-
cal coherence tomography (OCT) with the device Spectralis SD-OCT (Heidelberg Engineering, Heidelberg, 
Germany) under mesopic conditions. Firstly, vault estimations were measured under normal conditions 
(Nvault), with the patient focusing on an internal fixation point. Then instillations of one drop of cyclopentolate 
at 10-minute intervals were applied (3 instillations in all). Forty minutes after the first instillation, a second vault 
estimation was performed with cycloplegia (Cvault). Vault measurements were taken perpendicularly to the ICL 
and centred on the hole. The same technician (B.G.M.) assessed three different vault measurements under the 
two distinct conditions (pre and postcycloplegia) and calculated the mean vault value in each case. The difference 
between the mean Cvault and the mean Nvault (Cvault-Nvault) was calculated for each eye and referred to as 
∆vault.
Statistical analysis. A statistical analysis was performed using the SPSS software, version 19.0 (SPSS Inc.). 
Data distribution normality was confirmed by the Shapiro-Wilk test. The difference between the Nvault and 
Cvault measurements was studied by a paired-samples Student’s t-test. ∆vault was correlated with Nvault, ACD, 
pachymetry, pupillary diameter, ICL size and power, difference between W-W and ICL size (WW-size) and 
patient’s age using the Pearson coefficient correlation test. In order to evaluate the effect of the different vari-
ables on ∆vault, the sample was divided into two groups based on the dependent variables. The cutoff values 
(Nvault, 511 µm; ACD, 3.13 mm; pupil, 6.00 mm; W-W size, 1.1 mm) were arbitrarily set based on the 50th per-
centile value. The mean difference of these mentioned variables between these created groups was also studied 
by the independent-sample Student’s t-test. The mean difference of ∆vault between ICL sizes was analysed by an 
ANOVA test, followed by the Scheffe post hoc test. Multiple linear regression was finally performed. P ≤ 0.05 was 
considered statistically significant.
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